Step Down Colon Cancer Risk
Primary Purpose
Adenomatous Polyps
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Walking
Sponsored by
About this trial
This is an interventional prevention trial for Adenomatous Polyps
Eligibility Criteria
Inclusion Criteria:
- aged 50 to 80
- no personal cancer history
- found to have an adenomatous polyp upon colonoscopy at BJH/WUSM in the previous six months
- no contraindications to beginning an exercise program
- no previous diagnosis of familial polyposis syndromes
- no previous diagnosis of ulcerative colitis or Crohn's disease;
Exclusion Criteria:
- Participants who are regular NSAID users will be excluded as this may interfere with the measurement of inflammatory marker outcomes. Regular use is defined as taking 80mg or more per day of aspirin, ibuprofen, naproxen or other NSAID 5 or more days of the week.
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Arm A: 30 minutes walking
Arm B: 60 minutes walking
Arm Description
First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
Outcomes
Primary Outcome Measures
Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.
Changes in serum levels of four risk-related biomarkers: insulin, C-peptide, IL-6 and PGE-2 comparing baseline and 3 months serum levels.
Secondary Outcome Measures
Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.
Comparing changes in the secondary outcome of physical activity over three months, as measured by pedometer and accelerometer.
Full Information
NCT ID
NCT01476631
First Posted
November 9, 2011
Last Updated
August 2, 2013
Sponsor
Washington University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT01476631
Brief Title
Step Down Colon Cancer Risk
Official Title
Step Down Colon Cancer Risk: A Pilot Intervention for Colon Cancer Risk Reduction
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Terminated
Why Stopped
not enough patients consented during the funding period
Study Start Date
November 2008 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypothesis 1: Exercise will decrease serum markers in a dose response manner.
Hypothesis 2: Participants in the 60 minute intervention will have significantly higher physical activity levels than those in the 30 minute intervention at three months.
Detailed Description
Primary Aim: To conduct a dose response pilot trial of low (30 min/day) or high (60 min/day) dose exercise in men and women at increased risk of colon cancer. The major outcomes are changes in serum levels of four risk-related biomarkers: insulin, C-peptide, IL-6 and PGE-2.
Secondary Aim. To compare changes in the secondary outcome of physical activity over three months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenomatous Polyps
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm A: 30 minutes walking
Arm Type
Experimental
Arm Description
First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
Arm Title
Arm B: 60 minutes walking
Arm Type
Experimental
Arm Description
First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
Intervention Type
Behavioral
Intervention Name(s)
Walking
Intervention Description
7 days prior to baseline participants must wear a blinded pedometer
At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale.
Primary Outcome Measure Information:
Title
Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.
Description
Changes in serum levels of four risk-related biomarkers: insulin, C-peptide, IL-6 and PGE-2 comparing baseline and 3 months serum levels.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.
Description
Comparing changes in the secondary outcome of physical activity over three months, as measured by pedometer and accelerometer.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
aged 50 to 80
no personal cancer history
found to have an adenomatous polyp upon colonoscopy at BJH/WUSM in the previous six months
no contraindications to beginning an exercise program
no previous diagnosis of familial polyposis syndromes
no previous diagnosis of ulcerative colitis or Crohn's disease;
Exclusion Criteria:
Participants who are regular NSAID users will be excluded as this may interfere with the measurement of inflammatory marker outcomes. Regular use is defined as taking 80mg or more per day of aspirin, ibuprofen, naproxen or other NSAID 5 or more days of the week.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathleen Y. Wolin, ScD, FACSM
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
22808053
Citation
Wolin KY, Fagin C, James AS, Early DS. Promoting physical activity in patients with colon adenomas: a randomized pilot intervention trial. PLoS One. 2012;7(7):e39719. doi: 10.1371/journal.pone.0039719. Epub 2012 Jul 13.
Results Reference
derived
Links:
URL
http://www.siteman.wustl.edu
Description
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Learn more about this trial
Step Down Colon Cancer Risk
We'll reach out to this number within 24 hrs